Regeneron price target raised to $700 from $615 at Wells Fargo

Wells Fargo analyst Mohit Bansal raised the firm’s price target on Regeneron (REGN) to $700 from $615 and keeps an Equal Weight rating on the shares. The firm thinks RVO and Q4W approval is a big positive for Regeneron, as Street and even the company were expecting Q1 2026 approval at earliest. Wells believes it gives Eylea HD one full year to strengthen its position before multiple Eylea biosimilars come in.